** Shares of drugmaker Insmed INSM.O rise 24.9% to $88.28 premarket
** Co says its treprostinil palmitil inhalation powder (TPIP) met the main goal in a mid-stage trial by reducing blood flow resistance in the lungs by 35% when compared to placebo
** The drug was tested in patients with Pulmonary Arterial Hypertension (PAH), a rare disease caused by a constriction of arteries in the lungs, leading to high blood pressure
** Co says the treatment is administered once-daily in a capsule-based inhalation device
** INSM says it plans to initiate a late-stage trial for the drug in early 2026
** Up to last close, stock up 2.4% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。